Course 1 and Course 2: IdaDCTER is idarubicin 5 mg/m² per day infused more than half an hour daily, cytarabine 200 mg/m² /day and etoposide 100 mg/m² per day both as continuous 96-hour infusions (CI), oral thioguanine 100 mg/m² per day, and dexamethasone 6 mg/m²on days 0 to 3. On days 10 to 13, daunorubicin 20 mg/m² day CI replaces idarubicin. Course 2: FAMP is fludarabine monophosphate, 10.5 mg/m² loading dose, then 30.5 mg/m² per 24 hours for a total of 48 hours, followed by beginning Ara-C 390 mg/m² loading dose and 2400 mg/m² per 24 hours continuous infusion for 72 hours and idarubicin 12 mg/m² per day infused more than half an hour on days 0, 1, and 2 at 12.0 mg/m² per day. G-CSF, 5 μg/kg per day, initiated in patients with less than 5% residual leukemic blasts in day 14 ± 1 marrow and continued until neutrophil recovery. HidAC is cytarabine 3 g/m² as 3-hour infusions at hours 0 to 3, 12 to 15, 24 to 27, and 36 to 39 on days 0 and 7 followed by Escherichia coli L-asparaginase 6000 units/m² intramuscularly at hour 42 given on days 1 and 8. Marrow transplantation cytoreduction consists of 16 doses of busulfan at 40 mg/m² orally every 6 hours on days −9, −8, −7, and −6 and cyclophosphamide 50 mg/kg IV more than one hour on days −5,−4,−3, and −2; interleukin-2 is 9 × 10⁶ IU/m² per day CI day 0 to 3 and 1.6 × 10⁶ IU/m² per day on CI days 8 to 17. Central nervous system prophylaxis was intrathecal cytarabine on days 0 and 10 of course 1 and course 2 regimen A and weekly times 3 following recovering of counts after HidAC.^14,61  In courses 1 and 2, G-CSF, 5 μg/m² per day was started 48 hours after completion of chemotherapy and continued until the neutrophil count was more than 1500 × 10⁹/L.